At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)

Neurochem Annual and Special Meeting web cast live LAVAL, QC, April 15 /PRNewswire-FirstCall/ - At the Annual and Special meeting of Neurochem Inc. (NASDAQ: NRMX ; TSX: NRM), shareholders will be asked to officially adopt the Company's new name, BELLUS Health Inc., which it expects...

BELLUS Health reports results for the fourth quarter of 2008

...for the fourth quarter of 2008 BELLUS Health Inc., formerly known as neurochem Inc., (BELLUS Health or the Company) is a global health company focused on ...ive health solutions to address critical unmet needs. The shareholders of neurochem Inc. approved the change of its name to "BELLUS Health Inc." at the annual ...

BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market

...f management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s (formerly known as neurochem Inc.) control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or n...

BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update

...Highlights BELLUS Health Inc., formerly known as neurochem Inc., (BELLUS Health or the Company) is a global h...ddress critical unmet needs. The shareholders of neurochem Inc. approved the change of its name to "BELLUS He...are beyond BELLUS Health Inc.'s (formerly known as neurochem Inc.) control. Such risks include but are not limi...

BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference

...f management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s (formerly known as neurochem Inc.) control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or n...

BELLUS Health provides update on activities

...f management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s (formerly known as neurochem Inc.) control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or n...

BELLUS Health announces closing of Innodia acquisition

...-FirstCall/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU, formerly known as neurochem Inc.) announced today the closing of the acquisition of Innodia Inc. that i...d unknown, many of which are beyond BELLUS Health Inc.'s (formerly known as neurochem Inc.) control. Such risks include but are not limited to: the impact of gen...

BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference

...-FirstCall/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU, formerly known as neurochem Inc.) announces today that on Monday, May 19, 2008, Dr. Francesco Bellini, ...d unknown, many of which are beyond BELLUS Health Inc.'s (formerly known as neurochem Inc.) control. Such risks include but are not limited to: the impact of gen...

BELLUS HEALTH reports results for first quarter of fiscal 2008

...th Inc. (NASDAQ: BLUS; TSX: BLU, formerly known as neurochem Inc.) reported results for the first quarter ended...Financial Results Highlights The shareholders of neurochem Inc. approved the change of its name to "BELLUS He...are beyond BELLUS Health Inc.'s (formerly known as neurochem Inc.) control. Such risks include but are not limi...

Media advisory - Neurochem's Annual and Special Meeting of Shareholders April 15, 2008

... LAVAL, QC, April 11 /PRNewswire-FirstCall/ - Dr. Francesco Bellini, Chairman, President and Chief Executive Officer of neurochem Inc., invites the news media to the Annual and Special Meeting of Shareholders to be held on Tuesday, April 15, 2008, at 10:00 A.M., in the Maxwell-Cu...

Neurochem in Medical Technology

Immtech Reports Fiscal Second Quarter 2008 Results

...,753,000 for the three months ended June 30, 2006. The three month period ended September 30, 2006 included a receivable of $1,874,000 relating to the neurochem litigation award. Net loss attributable to common stockholders for the three months ended September 30, 2007 was $3,469,000, or $0.23 per share, compa...

Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis

... Limited (Neurochem), a wholly-owned subsidiary of neurochem Inc. , announces that the New England Journal of M...s of diagnosis. The EFAAT study was sponsored by neurochem Inc., and in part by a CDN$1.4 million grant from the U.S. Food and Drug Administration. About neurochem ...

At the 2007 Alzheimer's Association International Conference on the Prevention of Dementia - Neurochem's U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)

...and principal investigator in the United States of neurochem Inc.'s North American Phase III clinical trial for... Phase III clinical trial and provide an update. neurochem announced in April 2007 that an adjustment to the ...regarding the outcome of the Phase III study. neurochem continues to expect to announce the top-line resul...

Neurochem in Biological Technology

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As Revised)

...: SIRT ) SuperGen Inc. (Nasdaq: SUPG ) Transition Therapeutics Inc. (Nasdaq: TTHI ) XOMA Ltd. (Nasdaq: XOMA ) Neuroscience Index (HHN) Drop neurochem Inc. (Nasdaq: NRMX ) Add Caraco Pharmaceutical Laboratories Ltd. (Amex: CPD ) Ophthalmology Index (HHZ) Drop Insite Vision Inc. (Amex: ISV ) ...

Neurochem in Biological Products

QXL 520 C2 maleimide from AnaSpec

Description:...izing differences in ligand-induced beta-arrestin-GFP interactions and trafficking between three recently characterized G protein-coupled receptors. J neurochem 77, 476-85; Nasarabadi S, et al. (1999). Simultaneous detection of TaqMan probes containing FAM and TAMRA reporter fluorophores. Biotechniques 27, 111...
Company:AnaSpec

Neurochem in Biological Definition

Long-term potentiation

... ^ Sweatt JD (2001) "The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory". J neurochem 76 (1), 1-10. PMID 11145972 ^ PMID 10545144 ^ Malenka RC, Kauer JA, Perkel DJ, Mauk MD, Kelly PT, Nicoll RA, Waxham MN (1989)...